SUCLG2 identified as both a determinator of CSF A?1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, Popp J, Lacour A, Drichel D, Louwersheimer E, Kummer MP, Cruchaga C, Hoffmann P, Teunissen C, Holstege H, Kornhuber J, Peters O, Naj AC, Chouraki V, Bellenguez C, Gerrish A, Heun R, Fr?lich L, H?ll M, Buscemi L, Herms S, K?lsch H, Scheltens P, Breteler MM, R?ther E, Wiltfang J, Goate A, Jessen F, Maier W, Heneka MT, Becker T, N?then MM. SUCLG2 identified as both a determinator of CSF A?1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Hum Mol Genet. 2014 Dec 15; 23(24):6644-58.